UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nuclear/radiological terrorism: Emergency department management of radiation casualties

The Journal of emergency medicine, 2007, Vol.32 (1), p.71-85

2007

Volltextzugriff (PDF)

Synergy of Taxol and Radioimmunotherapy with Yttrium-90-Labeled Chimeric L6 Antibody: Efficacy and Toxicity in Breast Cancer Xenografts

Proceedings of the National Academy of Sciences - PNAS, 1997-04, Vol.94 (8), p.4000-4004

1997

Volltextzugriff (PDF)

Selection and Characterization of Anti-MUC-1 scFvs Intended for Targeted Therapy

Clinical cancer research, 2003-09, Vol.9 (10), p.3845s-53S

2003

Volltextzugriff (PDF)

Characterization of Human IgG Antimouse Antibody in Patients with B-Cell Malignancies

Clinical cancer research, 2003-09, Vol.9 (10), p.4013s-21S

2003

Volltextzugriff (PDF)

A new era for radiolabeled antibodies in cancer?

Current Opinion in Immunology, 1999-10, Vol.11 (5), p.563-569

1999

Volltextzugriff (PDF)

Planning Time for Peripheral Blood Stem Cell Infusion After High-Dose Targeted Radionuclide Therapy Using Dosimetry

The Journal of nuclear medicine (1978), 2005-06, Vol.46 (6), p.1034-1041

2005

Volltextzugriff (PDF)

Radiation dosimetry for (90)Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using (111)In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma

The Journal of nuclear medicine (1978), 2000-05, Vol.41 (5), p.952

2000

Volltextzugriff (PDF)

Strategies for Developing Effective Radioimmunotherapy for Solid Tumors

Clinical cancer research, 1999-10, Vol.5 (10), p.3219s-3223s

1999

Volltextzugriff (PDF)

Antibody Phage Libraries for the Next Generation of Tumor Targeting Radioimmunotherapeutics

Clinical cancer research, 1999-10, Vol.5 (10), p.3213s-3218s

1999

Volltextzugriff (PDF)

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

Journal of clinical oncology, 1998-10, Vol.16 (10), p.3246-3256

1998

Volltextzugriff (PDF)

Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies

Cancer research (Chicago, Ill.), 1995-12, Vol.55 (23 Suppl), p.5893s-5898s

1995

Volltextzugriff (PDF)

Influence of a peptide linker on biodistribution and metabolism of antibody-conjugated benzyl-EDTA. Comparison of enzymic digestion in vitro and in vivo

Bioconjugate chemistry, 1992-09, Vol.3 (5), p.424-429

1992

Volltextzugriff (PDF)

Apoptosis-related gene and protein expression in human lymphoma xenografts (raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy

Cancer biotherapy & radiopharmaceuticals, 2001-06, Vol.16 (3), p.213-225

2001

Volltextzugriff (PDF)

Overview of radiation myelotoxicity secondary to radioimmunotherapy using131 i-lym-1 as a model

Cancer, 1994-02, Vol.73 (S3), p.1038-1048

1994

Volltextzugriff (PDF)

Increased survival associated with radiolabeled lym‐1 therapy for non‐hodgkin's lymphoma and chronic lymphocytic leukemia

Cancer, 1997-12, Vol.80 (S12), p.2706-2711

1997

Volltextzugriff (PDF)

Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma

Cancer biotherapy & radiopharmaceuticals, 2007-08, Vol.22 (4), p.521

2007

Volltextzugriff (PDF)

Effect of Antilymphoma Antibody, 131 I-Lym-1, on Peripheral Blood Lymphocytes in Patients with Non-Hodgkin's Lymphoma

Cancer biotherapy & radiopharmaceuticals, 2007-08, Vol.22 (4), p.521-530

2007

Volltextzugriff (PDF)

Low-dose, Fractionated Radioimmunotherapy for B-cell Malignancies using I-LYM-1 Antibody

Cancer biotherapy & radiopharmaceuticals, 1998-01, Vol.13 (4), p.239-254

1998

Volltextzugriff (PDF)

Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody

Anticancer research, 1997-05, Vol.17 (3B), p.1745

1997

Volltextzugriff (PDF)

Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts

Blood, 2003-05, Vol.101 (9), p.3641-3647

2003

Volltextzugriff (PDF)

Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of90Y-DOTA-peptide-Lym-1 in lymphoma xenografts

Blood, 2003-05, Vol.101 (9), p.3641-3647

2003

Volltextzugriff (PDF)

Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy

Cancer biotherapy & radiopharmaceuticals, 2000-02, Vol.15 (1), p.71-79

2000

Volltextzugriff (PDF)

Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies

Clinical cancer research, 1997-08, Vol.3 (8), p.1253-1260

1997

Volltextzugriff (PDF)

The biologic window for chimeric l6 radioimmunotherapy

Cancer, 1994-02, Vol.73 (S3), p.1023-1032

1994

Volltextzugriff (PDF)

Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma

Cancer, 1997-12, Vol.80 (S12), p.2583-2590

1997

Volltextzugriff (PDF)

1 – 25 von 170

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(153)
Mit Volltextzugriff
(155)

Publikationsform

Sprache

Englisch
(170)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Nuclear/radiological terrorism: Emergency department management of radiation casualties

Synergy of Taxol and Radioimmunotherapy with Yttrium-90-Labeled Chimeric L6 Antibody: Efficacy and Toxicity in Breast Cancer Xenografts

Selection and Characterization of Anti-MUC-1 scFvs Intended for Targeted Therapy

Characterization of Human IgG Antimouse Antibody in Patients with B-Cell Malignancies

A new era for radiolabeled antibodies in cancer?

Planning Time for Peripheral Blood Stem Cell Infusion After High-Dose Targeted Radionuclide Therapy Using Dosimetry

Radiation dosimetry for (90)Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using (111)In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma

Strategies for Developing Effective Radioimmunotherapy for Solid Tumors

Antibody Phage Libraries for the Next Generation of Tumor Targeting Radioimmunotherapeutics

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies

Influence of a peptide linker on biodistribution and metabolism of antibody-conjugated benzyl-EDTA. Comparison of enzymic digestion in vitro and in vivo

Apoptosis-related gene and protein expression in human lymphoma xenografts (raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy

Overview of radiation myelotoxicity secondary to radioimmunotherapy using131 i-lym-1 as a model

Increased survival associated with radiolabeled lym‐1 therapy for non‐hodgkin's lymphoma and chronic lymphocytic leukemia

Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma

Effect of Antilymphoma Antibody, 131 I-Lym-1, on Peripheral Blood Lymphocytes in Patients with Non-Hodgkin's Lymphoma

Low-dose, Fractionated Radioimmunotherapy for B-cell Malignancies using I-LYM-1 Antibody

Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody

Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts

Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of90Y-DOTA-peptide-Lym-1 in lymphoma xenografts

Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy

Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies

The biologic window for chimeric l6 radioimmunotherapy

Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma

Suchergebnisse filtern